STAR-221 will evaluate domvanalimab plus zimberelimab and chemotherapy for the first-line treatment of patients with gastric, GEJ, or esophageal adenocarcinoma.
Spotlight on the STAR-221 Trial in Gastric/GEJ/Esophageal Adenocarcinoma
Sam Klempner, MD, discusses the ongoing evaluation of domvanalimab plus zimberelimab and chemotherapy in upper GI cancers.
Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.
Kohei Shitara, MD, discusses the investigation of domvanalimab plus zimberelimab and chemotherapy in patients with gastric/GEJ/esophageal cancers.
Kohei Shitara, MD, details the mechanisms of action of the investigational therapies domvanalimab and zimberelimab for gastrointestinal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5